Trastuzumab (Herceptin) Pharmacokinetic ELISA
Trastuzumab (Herceptin®) is indicated for the treatment of HER2-positive breast cancer, and adjuvant therapies for metastatic gastric cancer and gastroesophageal cancer. Serum concentration of Trastuzumab may predict some clinical outcome during therapy. It is also possible that the surveillance of circulating Trastuzumab concentration during therapy represents a direct factor for immunogenicity and some other side effects. Identification of biomarkers and risk factors for adverse drug reactions that might be related to serum concentrations, and maintaining the effective minimum concentration of Trastuzumab in order to potentially avoid some side effects, might be beneficial using a reliable method.
Product Specifications
CAS Number
7732-18-5
Gene ID
2064
Reactivity
Human, mouse, rat
Reaction Volume
15 µL
Target Antigen
Trastuzumab (Herceptin)
Detection Method
Peroxidase / OD450
Assay Type
ELISA
Assay Principle
Quantification of Trastuzumab in biological matrices
Assay Protocol
Assay Performance Time
2.5 hours
Sample Type
Serum Plasma
Sample Volume
15ul
Detection Range
40ng/ml - 1.25ng/ml
Precision
<10%, <10%
Sensitivity
Trastuzumab
Limit Of Detection
1.25ng/ml
Components
Shipping Conditions
Blue Ice
Storage Conditions
-20C, 1 year
Shelf Life
12 months
Badge
Hot
Specificity
Trastuzumab
Method
Direct sandwich ELISA
Preservative
None
Preparation
Operating Procedure
Results Calculation
Sample Collection
This kit is compatible with EDTA-plasma, heparinplasma and serum samples. Samples can be stored at or below -20°C for up to 1 year.
Sample Preparation
Plate
Strip
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items